Leuprorelin (leuprolide acetate) is a GnRH analogue that causes a brief initial rise in gonadotrophins and then, with continued use, pituitary desensitisation and suppressed sex hormones; it is used in advanced prostate cancer, endometriosis and central precocious puberty.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
Leuprorelin (leuprolide acetate) is a GnRH analogue that causes a brief initial rise in gonadotrophins and then, with continued use, pituitary desensitisation and suppressed sex hormones; it is used in advanced prostate cancer, endometriosis and central precocious puberty. · pmid:7533699
In the 48-week JASMITT trial in 199 men with spinal and bulbar muscular atrophy, leuprorelin did not significantly improve the primary swallowing measure against placebo. · pmid:20691641
Proportion of the 2 claims about Leuprolide (Leuprorelin) standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Leuprolide (Leuprorelin) yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. · pmid 20691641 · 2010
Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. · pmid 7533699 · 1994
Observational evidence· resolved human data at the emerging tier: thin, or contested
nothing resolved on this rung
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.